Pipeline

Ambrx has a number of highly differentiated product candidates at various stages of development in its pipeline, with a focus on discovering and developing best-in-class biopharmaceutical product opportunities. We also have a number of undisclosed partnerships with assets at various stages of development.

DEVELOPMENT PIPELINE

Stage	Product	Partner

	ARX788 αHER2 ADC – HER2+Breast Cancer⁽¹⁾
	ARX517 PSMA ADC - Oncology⁽²⁾
	CD70 ADC - Oncology⁽³⁾
	Bi-specific Anti-CD3 X Folate
	ARX618 PEG-FGF21 – NASH
	ARX720 Relaxin – Heart Failure
	Imrestor - Mastitis in Cattle⁽⁷⁾
	ADCs – Oncology
	Multi-Specific ADCs⁽⁹⁾
(1) Ambrx owns the worldwide rights to ARX788, with the exception of the People's Republic Of China, for which the rights to ARX788 have been licensed to Zhejiang Medicine Co., Ltd. (2) Potential indications include prostate cancer and glioblastoma multiforme. (3) Potential indications include renal cell carcinoma and nasopharyngeal carcinoma. (8) Potential indications include oncology and autoimune/inflamatory diseases.

Key	Description
	Marketed
	Phase 2
	Phase 1
	Preclinical
	Discovery

Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Marketed

Ambrx ADC and Bi-Specific Product Candidates
ARX788 αHER2 ADC – HER2+Breast Cancer⁽¹⁾
ARX517 PSMA ADC - Oncology⁽²⁾
CD70 ADC - Oncology⁽³⁾
Bi-specific Anti-CD3 X Folate
Collaboration Product and Product Candidates
ARX618 PEG-FGF21 – NASH
ARX720 Relaxin – Heart Failure
Imrestor - Mastitis in Cattle⁽⁶⁾
Other Early-Stage Programs
ADCs – Oncology
Multi-Specific ADCs⁽⁸⁾
(1) Ambrx owns the worldwide rights to ARX788, with the exception of the People's Republic Of China, for which the rights to ARX788 have been licensed to Zhejiang Medicine Co., Ltd. (2) Potential indications include prostate cancer and glioblastoma multiforme. (3) Potential indications include renal cell carcinoma and nasopharyngeal carcinoma. (6) Under this collaboration, Elanco Animal Health, a division of Eli Lilly & CO., has multiple projects directed at metabolic, infectious and inflamatory diseases in livestock and companion animals in early-stage clinical development, but we do not expect any of these other product candidates to launch before 2017. (8) Potential indications include hematologic and solid tumor cancers.